Your browser doesn't support javascript.
loading
Risk of Cancer in Patients With Crohn's Disease 30 Years After Diagnosis (the IBSEN Study).
Follin-Arbelet, Benoit; Cvancarova Småstuen, Milada; Hovde, Øistein; Jelsness-Jørgensen, Lars-Petter; Moum, Bjørn.
Afiliação
  • Follin-Arbelet B; Institute of Clinical Medicine, University of Oslo, Oslo, Norway.
  • Cvancarova Småstuen M; Department of Gastroenterology, Oslo University Hospital, Oslo, Norway.
  • Hovde Ø; Østfold University College, Halden, Norway.
  • Jelsness-Jørgensen LP; Institute of Clinical Medicine, University of Oslo, Oslo, Norway.
  • Moum B; Department of Public Health Oslo Metropolitan University, Oslo, Norway.
Crohns Colitis 360 ; 5(4): otad057, 2023 Oct.
Article em En | MEDLINE | ID: mdl-37886706
ABSTRACT

Background:

Patients with Crohn's disease (CD) are most often diagnosed as young adults; therefore, long-term studies are needed to assess the risk of cancer over their lifetime. Thus, the aims of the present study were to determine the risk of cancer in a Norwegian population-based cohort (the Inflammatory Bowel South Eastern Norway [IBSEN] study), 30 years after diagnosis, and to assess whether patients with CD were at an increased risk of specific cancer types.

Methods:

The IBSEN cohort prospectively included all incident patients diagnosed between 1990 and 1993. Data on cancer incidence were obtained from the Cancer Registry of Norway. Overall and cancer-specific hazard ratios (HRs) for CD patients compared with age- and sex-matched controls were modeled using Cox regression. Standardized incidence ratios (SIRs) were estimated compared to the general population.

Results:

In total, the cohort included 237 patients with CD, and 36 of them were diagnosed with cancer. Compared to the general Norwegian population, patients with CD had an increased overall risk of cancer (HR = 1.56, 95% CI 1.06-2.28), particularly male patients (HR = 1.85, 95% CI 1.08-3.16). The incidence of lung cancer and nonmelanoma skin cancer was increased; however, the difference was not statistically significant (SIR = 2.29, 95% CI 0.92-4.27 and SIR = 2.45, 95% CI 0.67-5.37, respectively).

Conclusions:

After 30 years of follow-up, the risk of all cancers in patients with CD was increased compared to the general population.
Palavras-chave

Texto completo: 1 Base de dados: MEDLINE Idioma: En Ano de publicação: 2023 Tipo de documento: Article País de afiliação: Noruega

Texto completo: 1 Base de dados: MEDLINE Idioma: En Ano de publicação: 2023 Tipo de documento: Article País de afiliação: Noruega